NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Phathom Pharmaceuticals, Inc. PHAT
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$175.1M
▲ 216.9% vs FY2024
EPS · FY25
$-3.03
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-126.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 175.1M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 126 cents on every revenue dollar this year.
Per share
USD -3.03
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-91.4%
Net margin-126.3%
Return on assets-69.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+150.5%
Change, 10 years—
The share count grew 150% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 259.1M
total assets, end of FY2025
Total assetsUSD 259.1M
EquityUSD -438.2M
CashUSD 130.0M
Gross debtUSD 209.1M
Net debtUSD 79.1M
Current ratio1.73×
Net debt stands at -18% of equity.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.2
0.1
0.0
0.0
·
·
·
·
Operating income $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.3
−0.0
EPS, diluted $
−3.03
−5.29
−3.93
−5.05
−3.89
−3.88
−22.45
−0.21
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
−108.0
−61.1
−225.1
·
Shares out B
0.07
0.07
0.06
0.04
0.03
0.03
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed